FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly to pharmacology, and concerns the new application of 5-ethoxy-2-[2-(morpholino)ethylthio]-benzimidazole dihydrochloride (the anxiolytic Afobazole) as a medication for withdrawal syndrome management in opiate dependence. It is shown that Afobazole administered in a single or sub-chronic dose decreases the manifestations of 'spontaneous' or naloxone-caused morphine withdrawal syndrome, i.e. decreases physical morphine dependence.
EFFECT: anxiolytic Afobazole represents an effective medication for correcting the clinical manifestations of opiate withdrawal syndrome.
3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS FOR OPIOID ABSTINENCE SYNDROME ARRESTING | 2017 |
|
RU2643588C1 |
| LOW-MOLECULAR MIMETIC BDNF AS AN AGENT FOR TREATING OPIOID DEPENDENCE | 2019 |
|
RU2707301C1 |
| DIMERIC DIPEPTIDE MIMETIC BDNF AS AGENT FOR TREATING AND PREVENTING OPIOID ADDICTION | 2023 |
|
RU2823374C1 |
| DRUG PREPARATION WITH CARDIOPROTECTIVE ACTIVITY | 2010 |
|
RU2476224C2 |
| IMMUNOGEN FOR TREATING AND PREVENTING OPIATE ADDICTION | 2013 |
|
RU2548802C1 |
| ANALGESIC AGENT AND THERAPY OF PAIN SYNDROME OF VARIOUS AETIOLOGIES BY USING SAID AGENT | 2007 |
|
RU2367432C2 |
| SYNTHETIC ANALGESIC AGENT AND METHOD FOR TREATMENT BASED ON THIS AGENT | 2006 |
|
RU2322977C1 |
| LOW MOLECULAR WEIGHT MIMETIC OF BRAIN NEUROTROPHIC FACTOR WITH ANALGESIC, ANXIOLYTIC AND ANTIADDICTIVE EFFECTS | 2020 |
|
RU2759023C2 |
| SIGMA-1 RECEPTOR AGONIST OF 5-ETHOXY-2-[2-(MORPHOLINO)ETHYLTHIO]-BENZIMIDAZOLE DIHYDROCHLORIDE AND/OR BASE - A NOVEL AGENT FOR PREVENTING SUDDEN CARDIAC DEATH IN PATIENTS SUFFERING ALCOHOLIC CARDIOMYOPATHY | 2017 |
|
RU2691636C1 |
| AGENT FOR CORRECTING AUTISM SPECTRUM DISORDERS | 2017 |
|
RU2666598C1 |
